Inrebic (Fedratinib) receives FDA Approval for Myelofibrosis

The First New Treatment in Nearly a Decade for MF Patients INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or […]

Imetelstat Active in Myeloproliferative Disorders

Essential thrombocythemia, myelofibrosis respond to telomere targeting Treatment with a drug that targets the chromosome-lengthening enzyme telomerase led to hematologic responses in all treated patients with essential thrombocythemia, a preliminary clinical trial showed. In 16 of 18 cases, patients achieved complete hematologic responses with imetelstat. Additionally, seven of eight patients with Janus kinase 2 (JAK2) […]

MPN Clinical Trials Moving Forward

Two MPN Clinical Trials Progress – Phase 3 Polycythemia Vera Study and Phase 2 Myelofibrosis Study There are dozens of clinical trials at various stages of progression for Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis.  Some are in the recruiting stage, others still active and the balance have been completed.  Both of these trials will be […]

 
error: Content is protected !